Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sarepta Therapeutics Inc (NASDAQ:SRPT)

23.89
Delayed Data
As of Jul 22
 +1.24 / +5.47%
Today’s Change
8.00
Today|||52-Week Range
41.97
-38.08%
Year-to-Date
Why Investors Flocked to Sarepta Therapeutics Last Week
Jul 21 / MotleyFool.com - Paid Partner Content
Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus
Jul 20 / Zacks.com - Paid Partner Content
Sarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss
Jul 20 / TheStreet.com - Paid Partner Content
3 Risky Biotech Stocks That Could Make You Rich
Jul 12 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close22.65
Today’s open22.91
Day’s range22.61 - 24.48
Volume3,094,681
Average volume (3 months)6,197,230
Market cap$1.1B
Dividend yield--
Data as of 3:59pm ET, 07/22/2016

Growth & Valuation

Earnings growth (last year)-53.39%
Earnings growth (this year)+10.72%
Earnings growth (next 5 years)+0.37%
Revenue growth (last year)-87.16%
P/E ratioNM
Price/Sales1,302.11
Price/Book5.73

Competitors

 Today’s
change
Today’s
% change
INSYINSYS Therapeutics I...+0.33+2.11%
LCILannett Company Inc-0.11-0.36%
ACHNAchillion Pharmaceut...-0.17-1.94%
ACORAcorda Therapeutics ...+0.19+0.75%
Data as of 4:01pm ET, 07/22/2016

Financials

Last reporting dateJuly 19, 2016
EPS forecast (this quarter)-$1.23
Annual revenue (last year)$1.3M
Annual profit (last year)-$220.0M
Net profit margin-17,560.26%

Profile

Sector
Health Technology
Industry
Biotechnology
Senior VP, Chief Executive &
Medical Officer
Edward M. Kaye
Head-Operations &
Vice President
Gavin T. Malenfant
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs